載入中
NASDAQHealthcareBiotechnology
最新資料
US$138.77
+US$7.43 · +5.66%
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
前收盤價
US$138.77
+US$7.43 · +5.66%
盤中時間採用ET。市場資料可能有所延遲。
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
日內區間
目前US$138.77
52週區間
目前US$138.77
盤中時間採用ET。市場資料可能有所延遲。
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
日內區間
目前US$138.77
52週區間
目前US$138.77
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 2590.2萬 USD | 3141.8萬 USD |
| 銷貨成本 | — | — | — | 278萬 USD | 236.8萬 USD |
| 毛利 | — | — | — | 2312.2萬 USD | 2905萬 USD |
| 研究與開發 | 2284.1萬 USD | 815.1萬 USD | 879.3萬 USD | 5021.2萬 USD | 6419.7萬 USD |
| 銷售、一般及管理費用 | 1576.1萬 USD | 594.4萬 USD | 307.6萬 USD | 1638.4萬 USD | 1668.4萬 USD |
| 營業費用 | 3860.2萬 USD | 1409.5萬 USD | 1186.9萬 USD | 6659.6萬 USD | 8088.1萬 USD |
| 利息收入 | 259萬 USD | 64.2萬 USD | 626.5萬 USD | 72.1萬 USD | 4000 USD |
| 利息支出 | 581.8萬 USD | 431.7萬 USD | — | — | — |
| 折舊和攤銷 | — | — | — | 278萬 USD | 236.8萬 USD |
| 營業利益 | −3860.2萬 USD | −1409.5萬 USD | −1186.9萬 USD | −4347.4萬 USD | −5183.1萬 USD |
| 淨利 | −4171.5萬 USD | −1743.4萬 USD | 1869.1萬 USD | −3327.7萬 USD | −4573.8萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年4月23日 | 1:80 | — | — |
已生效 2024年4月23日
1:80
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5937.44萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI4822.62萬0.49%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM4122.85萬0.05%787.4億 USD0.19%US$278.94+0.49%
iShares Russell 2000 Growth ETFIWO1442.28萬0.10%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO962.51萬0.05%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA852.4萬0.04%218.24億 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT484.47萬0.02%220億 USD0.09%US$319.01+1.64%
Vanguard U.S. Momentum Factor ETFVFMO350.8萬0.18%19億 USD0.13%US$230.11+1.02%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTVanguard U.S. Momentum Factor ETFVFMOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
